DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Clinical trial NCT06989112 · RECRUITING

Trial details

NCT number: NCT06989112
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Endometrial Cancer

Start date: 2025-03-27
Primary completion: 2029-01-19
Enrollment: 600

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.